allosteric

The group later identified the allosteric binding sites of calcium.

In this typical example, the allosteric enzyme can be thought of as a switch.

Such an enzyme is said to be 'allosteric': it can exist in two forms.

This protein may use the morpheein model of allosteric regulation.

As such, there are many different possible effectors when compared to allosteric systems of regulation.

It was further shown to act as an allosteric modulator of the sigma-1 receptor.

Allosteric modification usually happens in proteins with more than one subunit.

On the nature of allosteric transitions: a plausible model.

A good example is the allosteric regulation of the glycolytic pathway.

The second form of "non-competitive antagonists" act at an allosteric site.

Based on modulation, allosteric enzymes can be grouped into two groups: 1.

The morpheein model of allosteric regulation has similarities to and differences from other models.

This may be accomplished by binding to the active site or the allosteric site.

While for negative allosteric systems the binding of the first guest decreases the association constant with the second.

Several studies have also identified additional substrates that can act as allosteric effectors.

The mechanism of inhibition is competitive rather than allosteric.

Some allosteric proteins can be regulated by both their substrates and other molecules.

All allosteric binding sites are located in the large subunit of the enzyme.

It also suggests that the use of an imidazole-imidazolium conversion controls access to the allosteric B site.

The regulation of 1-phosphofructokinase occurs primarily by allosteric effectors, and is based on the cell's energy needs.

Glycogen phosphorylase was the first allosteric enzyme to be discovered.

Allosteric sites may represent a novel drug target.

Thus, I am assuming that P is an allosteric enhancer of the reaction.

Allosteric enhancers and inhibitors are common in biological systems.

These new insights also have implications in understanding allosteric effects and developing new medicines.